Rabies virus vaccine as an immune adjuvant against cancers and glioblastoma: new studies may resurrect a neglected potential


Altinoz M. A. , Guloksuz S., Elmaci I.

CLINICAL & TRANSLATIONAL ONCOLOGY, vol.19, no.7, pp.785-792, 2017 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Review
  • Volume: 19 Issue: 7
  • Publication Date: 2017
  • Doi Number: 10.1007/s12094-017-1613-6
  • Title of Journal : CLINICAL & TRANSLATIONAL ONCOLOGY
  • Page Numbers: pp.785-792

Abstract

To review the literature about the use of Rabies Virus-Vaccine (RV-V) as an anticancer immunotherapeutic modality in the light of recent findings. The literature search in relevant databases with the following key words: Rabies virus, cancer, remission. Remissions occured following RV-V injections in patients with cervical cancer and melanoma. Pilot clinical studies showed that RV-V injections enhanced survival in glioblastoma patients, which is supported by findings in GL261 mouse glioma model. If public health studies demonstrate protective role of RV-V against certain types of cancers, it can be benefitted as a novel immune adjuvant in clinic.